Selection of uremic toxin-reducing probiotics in vitro and in vivo

The aim of this study was to screen and select potential probiotics that are able to reduce uremic toxin levels, mainly indoxyl sulphate (IS), in vitro and in vivo. Three strains, Lactobacillus plantarum subsp. plantarum BCRC12251, Lb. paracasei subsp. paracasei BCRC12188 and Streptococcus salivarius subsp. thermophilus BCRC13869, were selected to have the ability to reduce indoxyl sulphate in vitro. Combination of strains demonstrated a better IS removing ability than individual strains. In vivo, we observed that oral administration of Pm1 in cisplatin-induced acute kidney injury model significantly suppressed the accumulation of IS in the serum. Our findings suggest that treatment with the strain combination Pm1 might be a useful approach to decreasing IS accumulation in the serum and kidney. Administration of Pm1 is also likely to be beneficial to chemotherapy patients who are being treated with cisplatin.